FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:105-114 July 10, 1997 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Until recently, long-term regimens consisting of daily intravenous infusions of ganciclovir or foscarnet were the only available treatments for patients with cytomegalovirus (CMV) retinitis, a sight-threatening complication that affects approximately one third of patients in the United States with the acquired immunodeficiency syndrome (AIDS).^1,2 In the past three years, the results of 11 randomized clinical trials of four new treatments for AIDS-related CMV retinitis have been reported.^{3,4,5,6,7,8,9,10,11,12,13} Thus, there are now new therapies from which clinicians can choose.

Incidence and Natural History of CMV Retinitis

CMV end-organ disease has emerged as one of the most common serious complications of AIDS, with an incidence similar to that of . . . [Full Text of this Article]

Antiviral Drugs

Mechanism of Action and Resistance

Pharmacokinetic and Pharmacodynamic Correlations

Effect of Long-Term Antiviral Therapy on the Natural History of Retinitis

Retinal Detachment

Ophthalmologic Measurement of Drug Efficacy

Initial Treatment of CMV Retinitis

Efficacy and Toxicity

Oral Ganciclovir

Intraocular Ganciclovir Implant

Cidofovir

Salvage Treatment of CMV Retinitis

Switching from Ganciclovir to Foscarnet

Combined Therapy with Intravenous Ganciclovir and Foscarnet

Cidofovir

Intraocular Injections of Ganciclovir or Foscarnet

Intraocular Ganciclovir Implant

Anti-CMV Drugs and Regimens in Development

Conclusions

Source Information

From the Department of Medicine, University of California, San Francisco, and the Medical Service, San Francisco General Hospital, San Francisco.

Address reprint requests to Dr. Jacobson at San Francisco General Hospital, Ward 84, 995 Potrero Ave., San Francisco, CA 94110.

References

This article has been cited by other articles:

• Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S. T., Otte, J.-M., Diebold, J., Diepolder, H., Adler, B., Auernhammer, C. J., Goke, B., Dambacher, J. (2005). IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G960-G968 [Abstract] [Full Text]  
• Williams-Aziz, S. L., Hartline, C. B., Harden, E. A., Daily, S. L., Prichard, M. N., Kushner, N. L., Beadle, J. R., Wan, W. B., Hostetler, K. Y., Kern, E. R. (2005). Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro. Antimicrob. Agents Chemother. 49: 3724-3733 [Abstract] [Full Text]  
• Springer, K. L., Chou, S., Li, S., Giller, R. H., Quinones, R., Shira, J. E., Weinberg, A. (2005). How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients. J. Clin. Microbiol. 43: 208-213 [Abstract] [Full Text]  
• Springer, K. L., Weinberg, A. (2004). Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J Antimicrob Chemother 54: 582-586 [Abstract] [Full Text]  
• Griffiths, P. D. (2002). The treatment of cytomegalovirus infection. J Antimicrob Chemother 49: 243-253 [Abstract] [Full Text]  
• Henry, S. P., Miner, R. C., Drew, W. L., Fitchett, J., York-Defalco, C., Rapp, L. M., Levin, A. A. (2001). Antiviral Activity and Ocular Kinetics of Antisense Oligonucleotides Designed to Inhibit CMV Replication. IOVS 42: 2646-2651 [Abstract] [Full Text]  
• Hillman, J. D., Peng, A. T., Gilliam, A. C., Remick, S. C. (2001). Treatment of Kaposi Sarcoma With Oral Administration of Shark Cartilage in a Human Herpesvirus 8-Seropositive, Human Immunodeficiency Virus-Seronegative Homosexual Man. Arch Dermatol 137: 1149-1152 [Full Text]  
• Liekens, S., Neyts, J., De Clercq, E., Verbeken, E., Ribatti, D., Presta, M. (2001). Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir. Cancer Res. 61: 5057-5064 [Abstract] [Full Text]  
• Nichols, W. G., Corey, L., Gooley, T., Drew, W. L., Miner, R., Huang, M.-L., Davis, C., Boeckh, M. (2001). Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 97: 867-874 [Abstract] [Full Text]  
• Bedard, J., May, S., L'Heureux, L., Stamminger, T., Copsey, A., Drach, J., Huffman, J., Chan, L., Jin, H., Rando, R. F. (2000). Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity against Human Cytomegalovirus. Antimicrob. Agents Chemother. 44: 929-937 [Abstract] [Full Text]  
• CUNNINGHAM, E. T JR (2000). Uveitis in HIV positive patients. Br. J. Ophthalmol. 84: 233-236 [Full Text]  
• MacCumber, M. W., Sadeghi, S., Cohen, J. A., Deutsch, T. A. (1999). Suture Loop to Aid in Ganciclovir Implant Removal. Arch Ophthalmol 117: 1250-1254 [Abstract] [Full Text]  
• Miller, D. M., Zhang, Y., Rahill, B. M., Waldman, W. J., Sedmak, D. D. (1999). Human Cytomegalovirus Inhibits IFN-{alpha}-Stimulated Antiviral and Immunoregulatory Responses by Blocking Multiple Levels of IFN-{alpha} Signal Transduction. J. Immunol. 162: 6107-6113 [Abstract] [Full Text]  
• Balfour, H. H. (1999). Antiviral Drugs. NEJM 340: 1255-1268 [Full Text]  
• Erice, A. (1999). Resistance of Human Cytomegalovirus to Antiviral Drugs. Clin. Microbiol. Rev. 12: 286-297 [Abstract] [Full Text]  
• Bedard, J., May, S., Lis, M., Tryphonas, L., Drach, J., Huffman, J., Sidwell, R., Chan, L., Bowlin, T., Rando, R. (1999). Comparative Study of the Anti-Human Cytomegalovirus Activities and Toxicities of a Tetrahydrofuran Phosphonate Analogue of Guanosine and Cidofovir. Antimicrob. Agents Chemother. 43: 557-567 [Abstract] [Full Text]  
• Bush, C. E., Sluchak-Carlsen, J. A. (1998). Evaluation of a Leukocyte Stabilization Reagent for Use in the Cytomegalovirus pp65 Antigenemia Assay. J. Clin. Microbiol. 36: 3410-3411 [Abstract] [Full Text]  
• (1998). Antiretroviral Therapy and Medical Management of Pediatric HIV Infection. Pediatrics 102: 1005-1062 [Full Text]  
• Cunningham, E. T., Margolis, T. P. (1998). Ocular Manifestations of HIV Infection. NEJM 339: 236-244 [Full Text]  
• Emery, V. C., Griffiths, P. D. (2000). Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl. Acad. Sci. USA 97: 8039-8044 [Abstract] [Full Text]